Jack Kaye sold $1.2M of QURE
director at uniQure N.V.. 38,810 shares at an average of $30.34, traded Nov 4, 2025, filed Nov 6, 2025.
Score components
- +15RoleDirector
- +25Trade size$1.2M at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000904454-25-000560, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 4, 2025 | MOption exercise Ordinary Shares10b5-1 | +10,000 | $7.37 | $74k | 30,439 | Nov 6, 2025 |
| Nov 4, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -10,000 | $30.36 | $304k | 20,439 | Nov 6, 2025 |
| Nov 4, 2025 | MOption exercise Ordinary Shares10b5-1 | +11,000 | $5.37 | $59k | 31,439 | Nov 6, 2025 |
| Nov 4, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -11,000 | $30.34 | $334k | 20,439 | Nov 6, 2025 |
| Nov 4, 2025 | MOption exercise Ordinary Shares10b5-1 | +17,810 | $14.08 | $251k | 38,249 | Nov 6, 2025 |
| Nov 4, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -17,810 | $30.33 | $540k | 20,439 | Nov 6, 2025 |
| Nov 4, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 0 | Nov 6, 2025 |
| Nov 4, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -11,000 | $0.00 | $0 | 0 | Nov 6, 2025 |
| Nov 4, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -17,810 | $0.00 | $0 | 0 | Nov 6, 2025 |
Related signals
Other insiders at uniQure N.V. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | QUREsell uniQure N.V. | Walid Abi-Saab Chief Medical Officer | $7,320 808 shares | -0% | |
| 15Weak | QUREsell uniQure N.V. | Walid Abi-Saab Chief Medical Officer | $17k 1,660 shares | -1% | |
| 10Weak | uniQure N.V. | Robert Gut director | $630k 25,613 shares | -44% | |
| 21Weak | uniQure N.V. | Robert Gut director | $857k 31,434 shares | -44% | |
| 19Weak | uniQure N.V. | Christian Klemt Chief Financial Officer | $945k 18,000 shares | -8% | |
| 33Weak | uniQure N.V. | Matthew C Kapusta CEO, Managing Director | $9.4M 226,316 shares | -26% | |
| 30Weak | uniQure N.V. | Walid Abi-Saab Chief Medical Officer | $20k 1,466 shares | -1% | |
| 35Weak | uniQure N.V. | Madhavan Balachandran director | $31k 2,112 shares | -5% | |
| 37Weak | uniQure N.V. | Robert Gut director | $48k 3,336 shares | -6% | |
| 35Weak | uniQure N.V. | Rachelle Suzanne Jacques director | $31k 2,112 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.